Review



anti-cd127 fitc (a019d5)  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Thermo Fisher anti-cd127 fitc (a019d5)
    Anti Cd127 Fitc (A019d5), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti-cd127+fitc+(a019d5)/anti+cd127+apc/pmc12133384-138-10-16
    Average 90 stars, based on 1 article reviews
    anti-cd127 fitc (a019d5) - by Bioz Stars, 2026-10
    90/100 stars

    Images



    Similar Products

    anti-cd127 fitc (a019d5)  (Thermo Fisher)
    90
    Thermo Fisher anti-cd127 fitc (a019d5)
    Anti Cd127 Fitc (A019d5), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti-cd127+fitc+(a019d5)/anti+cd127+apc/pmc12133384-138-10-16
    Average 90 stars, based on 1 article reviews
    anti-cd127 fitc (a019d5) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    anti-human cd127-fitc a019d5  (Miltenyi Biotec)
    90
    Miltenyi Biotec anti-human cd127-fitc a019d5
    To investigate the phenotype and subsets of CD4 + T cells in patients and healthy individuals, PBMCs were isolated from peripheral blood, incubated with CD4-ECD, CD25-PE-cy7, <t>CD127-FITC</t> or PD-1-PE, and analyzed by flow cytometry. ( A , B ) The percentage of CD4 + CD25 + CD127 low/− T cells was among the highest in PBMCs of IBCa patients (6.06 ± 2.17%) compared with FIBma patients (2.91 ± 1.06%) and health individuals (2.28 ± 0.79%) ( P < 0.05 for all). ( C , D ) The expression of PD-1 on CD4 + CD25 + CD127 low/− Tregs in PBMCs of health individuals, FIBma and IBCa patients analyzed by flow cytometry. These was significant difference between the PBMCs of FIBma patients and health individuals ( P < 0.05). ( E ) The percentages of CD4 + T cells in PBMCs of health individuals, FIBma and IBCa patients were 19.90 ± 9.02%, 22.98 ± 7.51%, and 20.74 ± 8.84%, respectively. And there no difference was found between health individuals and FIBma patients or health individuals and IBCa patients ( P > 0.05). ( F ) The ratio of CD4 + CD25 + CD127 low/− Tregs and CD4 + T cells was highest in PBMCs of IBCa patients compared with health individuals and FIBma ( P < 0.001). ( G , H ) The expression of PD-1 compartmentalized into two distinct (PD-1 lo and PD-1 hi ) populations. The high level PD-1 hi expression was found on CD4 + CD25 + CD127 + T cells (20.00 ± 22.15%) and CD4 + CD25 − T cells (13.92 ± 10.15%), compared with CD4 + CD25 + CD127 low/− Tregs (9.57 ± 7.27%). And there was significantly difference between CD4 + CD25 + CD127 low/− Tregs and CD4 + CD25 + CD127 + effector T cells ( P < 0.05). On the other hand, there was high level PD-1 lo expression was found on CD4 + CD25 + CD127 low/− Tregs (37.17 ± 19.27%), compared with CD4 + CD25 + CD127 + effector T cells (31.03 ± 20.84%) or CD4 + CD25 − T cells (23.87 ± 19.68%) ( P > 0.05 and P < 0.05, respectively).
    Anti Human Cd127 Fitc A019d5, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti-cd127+fitc+(a019d5)/cd127/pmc05071845-152-50-61
    Average 90 stars, based on 1 article reviews
    anti-human cd127-fitc a019d5 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    To investigate the phenotype and subsets of CD4 + T cells in patients and healthy individuals, PBMCs were isolated from peripheral blood, incubated with CD4-ECD, CD25-PE-cy7, CD127-FITC or PD-1-PE, and analyzed by flow cytometry. ( A , B ) The percentage of CD4 + CD25 + CD127 low/− T cells was among the highest in PBMCs of IBCa patients (6.06 ± 2.17%) compared with FIBma patients (2.91 ± 1.06%) and health individuals (2.28 ± 0.79%) ( P < 0.05 for all). ( C , D ) The expression of PD-1 on CD4 + CD25 + CD127 low/− Tregs in PBMCs of health individuals, FIBma and IBCa patients analyzed by flow cytometry. These was significant difference between the PBMCs of FIBma patients and health individuals ( P < 0.05). ( E ) The percentages of CD4 + T cells in PBMCs of health individuals, FIBma and IBCa patients were 19.90 ± 9.02%, 22.98 ± 7.51%, and 20.74 ± 8.84%, respectively. And there no difference was found between health individuals and FIBma patients or health individuals and IBCa patients ( P > 0.05). ( F ) The ratio of CD4 + CD25 + CD127 low/− Tregs and CD4 + T cells was highest in PBMCs of IBCa patients compared with health individuals and FIBma ( P < 0.001). ( G , H ) The expression of PD-1 compartmentalized into two distinct (PD-1 lo and PD-1 hi ) populations. The high level PD-1 hi expression was found on CD4 + CD25 + CD127 + T cells (20.00 ± 22.15%) and CD4 + CD25 − T cells (13.92 ± 10.15%), compared with CD4 + CD25 + CD127 low/− Tregs (9.57 ± 7.27%). And there was significantly difference between CD4 + CD25 + CD127 low/− Tregs and CD4 + CD25 + CD127 + effector T cells ( P < 0.05). On the other hand, there was high level PD-1 lo expression was found on CD4 + CD25 + CD127 low/− Tregs (37.17 ± 19.27%), compared with CD4 + CD25 + CD127 + effector T cells (31.03 ± 20.84%) or CD4 + CD25 − T cells (23.87 ± 19.68%) ( P > 0.05 and P < 0.05, respectively).

    Journal: Scientific Reports

    Article Title: PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer

    doi: 10.1038/srep35651

    Figure Lengend Snippet: To investigate the phenotype and subsets of CD4 + T cells in patients and healthy individuals, PBMCs were isolated from peripheral blood, incubated with CD4-ECD, CD25-PE-cy7, CD127-FITC or PD-1-PE, and analyzed by flow cytometry. ( A , B ) The percentage of CD4 + CD25 + CD127 low/− T cells was among the highest in PBMCs of IBCa patients (6.06 ± 2.17%) compared with FIBma patients (2.91 ± 1.06%) and health individuals (2.28 ± 0.79%) ( P < 0.05 for all). ( C , D ) The expression of PD-1 on CD4 + CD25 + CD127 low/− Tregs in PBMCs of health individuals, FIBma and IBCa patients analyzed by flow cytometry. These was significant difference between the PBMCs of FIBma patients and health individuals ( P < 0.05). ( E ) The percentages of CD4 + T cells in PBMCs of health individuals, FIBma and IBCa patients were 19.90 ± 9.02%, 22.98 ± 7.51%, and 20.74 ± 8.84%, respectively. And there no difference was found between health individuals and FIBma patients or health individuals and IBCa patients ( P > 0.05). ( F ) The ratio of CD4 + CD25 + CD127 low/− Tregs and CD4 + T cells was highest in PBMCs of IBCa patients compared with health individuals and FIBma ( P < 0.001). ( G , H ) The expression of PD-1 compartmentalized into two distinct (PD-1 lo and PD-1 hi ) populations. The high level PD-1 hi expression was found on CD4 + CD25 + CD127 + T cells (20.00 ± 22.15%) and CD4 + CD25 − T cells (13.92 ± 10.15%), compared with CD4 + CD25 + CD127 low/− Tregs (9.57 ± 7.27%). And there was significantly difference between CD4 + CD25 + CD127 low/− Tregs and CD4 + CD25 + CD127 + effector T cells ( P < 0.05). On the other hand, there was high level PD-1 lo expression was found on CD4 + CD25 + CD127 low/− Tregs (37.17 ± 19.27%), compared with CD4 + CD25 + CD127 + effector T cells (31.03 ± 20.84%) or CD4 + CD25 − T cells (23.87 ± 19.68%) ( P > 0.05 and P < 0.05, respectively).

    Article Snippet: The following monoclonal antibodies and reagents were used in this study: anti-human CD19-ECD (clone: J3-119) (Beckman Coulter Company, Marseille, France) and anti-human CD4-ECD (clone: SFCI12T411) were purchased from Beckman (USA); anti-human CD24-PE-cy7 (clone: eBioSN3), anti-human CD38-APC (clone: HIT2), and anti-human CD25-PE-cy7 (clone: BC96) were from eBiosciencs (San Jose, CA, USA); anti-human CD127-FITC (clone: A019D5) and anti-human PD-1-PE (clone: PD1.3.1.3) were from Miltenyi Biotec (Germany); PDL1-PE (clone: 29E.2A3) was obtained from BioLegend (USA).

    Techniques: Isolation, Incubation, Flow Cytometry, Expressing

    Relationship between the proportion of CD4 + T cells and its subset in PBMCs and the clinicopathological parameters of IBCa patients.

    Journal: Scientific Reports

    Article Title: PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer

    doi: 10.1038/srep35651

    Figure Lengend Snippet: Relationship between the proportion of CD4 + T cells and its subset in PBMCs and the clinicopathological parameters of IBCa patients.

    Article Snippet: The following monoclonal antibodies and reagents were used in this study: anti-human CD19-ECD (clone: J3-119) (Beckman Coulter Company, Marseille, France) and anti-human CD4-ECD (clone: SFCI12T411) were purchased from Beckman (USA); anti-human CD24-PE-cy7 (clone: eBioSN3), anti-human CD38-APC (clone: HIT2), and anti-human CD25-PE-cy7 (clone: BC96) were from eBiosciencs (San Jose, CA, USA); anti-human CD127-FITC (clone: A019D5) and anti-human PD-1-PE (clone: PD1.3.1.3) were from Miltenyi Biotec (Germany); PDL1-PE (clone: 29E.2A3) was obtained from BioLegend (USA).

    Techniques:

    ( A ) The positive correlation was found between the percentages of CD4 + T cells and CD19 + B cells ( r = 0.397, P < 0.001). ( B ) The positive correlation was found between CD4 + CD25 + CD127 low/− Tregs and CD19 + CD24 + CD38 + Bregs ( r = 0.316, P = 0.001). ( C ) The positive correlation was found between PD-L1 + Bregs and Bregs ( r = 0.267, P = 0.007). ( D ) The positive correlation was found between PD-L1 + Bregs and CD4 + CD25 + CD127 low/− Tregs ( r = 0.299, P = 0.003). ( E ) There was significantly negative correlation between PD-L1 + Bregs vs PD-1 hi CD4 + CD25 + CD127 + effector T cells ( r = −0.220, P = 0.031).

    Journal: Scientific Reports

    Article Title: PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer

    doi: 10.1038/srep35651

    Figure Lengend Snippet: ( A ) The positive correlation was found between the percentages of CD4 + T cells and CD19 + B cells ( r = 0.397, P < 0.001). ( B ) The positive correlation was found between CD4 + CD25 + CD127 low/− Tregs and CD19 + CD24 + CD38 + Bregs ( r = 0.316, P = 0.001). ( C ) The positive correlation was found between PD-L1 + Bregs and Bregs ( r = 0.267, P = 0.007). ( D ) The positive correlation was found between PD-L1 + Bregs and CD4 + CD25 + CD127 low/− Tregs ( r = 0.299, P = 0.003). ( E ) There was significantly negative correlation between PD-L1 + Bregs vs PD-1 hi CD4 + CD25 + CD127 + effector T cells ( r = −0.220, P = 0.031).

    Article Snippet: The following monoclonal antibodies and reagents were used in this study: anti-human CD19-ECD (clone: J3-119) (Beckman Coulter Company, Marseille, France) and anti-human CD4-ECD (clone: SFCI12T411) were purchased from Beckman (USA); anti-human CD24-PE-cy7 (clone: eBioSN3), anti-human CD38-APC (clone: HIT2), and anti-human CD25-PE-cy7 (clone: BC96) were from eBiosciencs (San Jose, CA, USA); anti-human CD127-FITC (clone: A019D5) and anti-human PD-1-PE (clone: PD1.3.1.3) were from Miltenyi Biotec (Germany); PDL1-PE (clone: 29E.2A3) was obtained from BioLegend (USA).

    Techniques: